Cannabis Oil Did Not Reduce Spasticity in Severe Cerebral Palsy Despite Being Well-Tolerated

No significant differences between FSCO and placebo in spasticity (Modified Ashworth Scale), motor function (GMFM-88), or quality of life parameters after 6 weeks of double-blind treatment. FSCO was generally well-tolerated with mild to moderate adverse events and no life-threatening events. Patients in the FSCO group were significantly drowsier.

Pilot feasibility study (7 patients) followed by prospective double-blind, placebo-controlled parallel trial with 53 participants aged 5-25 with spastic CP grades IV-V. 1:1 randomization. 6-week double-blind phase followed by 6-week open-label phase. Full-spectrum cannabis oil with 10:1 CBD:THC ratio.

Despite anecdotal reports and parent interest, this is one of the first rigorous RCTs testing cannabis for cerebral palsy spasticity. The null result is important for informing families and clinicians about realistic expectations.

The well-tolerated safety profile leaves open the possibility that different cannabinoid ratios, higher doses, or longer treatment periods might show efficacy, but the current evidence does not support cannabis oil for CP spasticity.

Small sample size. Only 6-week double-blind period. Fixed CBD:THC ratio may not be optimal. Grade IV-V CP represents the most severe forms, where spasticity may be least responsive. Single formulation tested.